Barrons
17 Aug 2026, 15:14 UTC · 3h ago
EyePoint Stock Craters 71% After Drug Trial Failure. It May Be an Overreaction.
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Barrons
17 Aug 2026, 15:14 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
EyePoint's drug candidate Duravyu failed to meet its primary endpoint in a trial for wet age-related macular degeneration. — Missing a primary endpoint in a clinical trial typically leads to significant valuation drops for biotech companies due to failure of the product pipeline.
-0.80The trial data for Duravyu was described as muddled, suggesting the failure may be due to data quality or trial design rather than drug efficacy. — While the failure is negative, the suggestion that data was muddled provides a small hedge that the drug might still be viable if re-tested.
+0.20Which stocks this story touches
The company's drug candidate Duravyu missed its trial marks for wet age-related macular degeneration.
Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
7h ago
